### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#### BEFORE THE PATENT TRIAL AND APPEAL BOARD

\_\_\_\_\_

COALITION FOR AFFORDABLE DRUGS VIII LLC, Petitioner

v.

TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA,
Patent Owner, based on Electronic Records of PTO
U.S. Patent 8,618,135 to Rader
Filing Date: March 11, 2011

Issue Date: December 31, 2013

TITLE: METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS

\_\_\_\_\_

Inter Partes Review No.: TBD

Declaration of Randall M. Zusman, M.D. in Support of Coalition for Affordable Drugs' Petition for *Inter Partes* Review of U.S. Patent No. 8,618,135



# TABLE OF CONTENTS

| I.    | INTRODUCTION1  |   |  |    |  |
|-------|--|---|--|----|--|
| II.   | MY EXPERIENCE AND QUALIFICATIONS                           |   |  |    |  |
| III.  | SUMMARY OF OPINIONS4                                       |   |  |    |  |
| IV.   | LIST OF MATERIALS CONSIDERED 8                             |   |  |    |  |
| V.    | PERS   | ERSON OF ORDINARY SKILL IN THE ART 8  |  |    |  |
| VI.   | BACKGROUND   |   |  |    |  |
|       | A.   | A. Drug development—the cardiologist's general perspective                                |  |    |  |
|       | B.   | Cardiovascular disease—non-surgical treatment options and targets available by March 2004 |  |    |  |
|       |  | 1.  | Fibrates   | 16 |  |
|       |  | 2.  | Niacin   | 17 |  |
|       |  | 3.  | Statins  | 18 |  |
|       |  | 4.  | Patient populations requiring more than just a statin drug | 19 |  |
|       |  | 5.  | MTP Inhibitors   | 21 |  |
|       |  | 6.  | MTP Inhibitors: Animal and Human Studies                   | 22 |  |
|       |  | 7.  | MTP Inhibitors: specific dosing considerations             | 24 |  |
| VII.  | THE 135 PATENT   |   |  |    |  |
|       | A.   | The 135 Patent File History   |  |    |  |
|       | B.   | The 915 Provisional Does Not Support the Claimed Escalating Dose Titration Regimen        |  |    |  |
|       | C.   | The Meaning of Certain 135 Patent Claim Terms43   |  |    |  |
| VIII. | COMPARISON BETWEEN THE 135 PATENT CLAIMS AND THE PRIOR ART |   |  |    |  |
|       | A.   | Discl   | osures, Knowledge and Information Available in the Art     | 45 |  |
|       |  | 1.  | Chang  | 46 |  |
|       |  | 2.  | Stein 2004   | 48 |  |



|    | 3. The Pink Sheet   |  |   | 51 |  |
|----|---|--|---|----|--|
| B. | The I   | Legal F  | Parameters of Obviousness   | 53 |  |
| C. | Obviousness of the 135 Patent Claims: Pink Sheet in view of Chang |  |   |    |  |
|    | 1.  | Subject matter claimed by the 135 Patent claim 1 would have been obvious to the person of ordinary skill |   | 58 |  |
|    |   | (a)  | "A method of treating a subject suffering from hyperlipidemia or hypercholesterolemia, the method comprising"   | 59 |  |
|    |   | (b)  | "Administering to the subject an effective amount of an MTP inhibitor"  | 60 |  |
|    |   | (c)  | "Wherein said administration comprises at least<br>three step-wise, increasing dose levels of the MTP<br>inhibitor "  | 61 |  |
|    |   | (d)  | "Wherein a first dose level is from about 2 to about 13 mg/day, a second dose level is from about 5 to about 30 mg/day, and a third dose level is from about 10 to about 50 mg/day" | 61 |  |
|    |   | (e)  | "Wherein the MTP inhibitor is represented by:   |    |  |
|    |   |  | or a pharmaceutically acceptable salt thereof or the piperidine N-oxide thereof"  | 62 |  |
|    |   | (f)  | "Wherein each dose level is administered to the subject for about 1 to about 5 weeks."  | 63 |  |
|    |   | (g)  | The ordinarily skilled artisan would be motivated to combine the Pink Sheet with Chang  | 63 |  |
|    |   | (h)  | The ordinarily skilled artisan would have a reasonable expectation of success   | 68 |  |
|    | 2.  | 135 F  | Patent Claim 2  | 70 |  |
|    | 3 135 Patent Claim 3  |  |   | 72 |  |



# Declaration of Randall M. Zusman, M.D. Petition for *Inter Partes* Review of U.S. Patent No. 8,618,135

|    | 4.  | 135                    | Patent Claim 4  | 74 |  |
|----|-----|------------------------|---|----|--|
|    | 5.  | 135                    | Patent Claim 5  | 75 |  |
|    | 6.  | 135                    | Patent Claim 6  | 75 |  |
|    | 7.  | 135 Patent Claim 7     |   |    |  |
|    | 8.  | 135                    | Patent Claim 8  | 77 |  |
|    | 9.  | 135                    | Patent Claim 9  | 79 |  |
|    | 10. | 0. 135 Patent Claim 10 |   |    |  |
| D. |     |                        | ss of 135 Patent Claims: Stein 2004 in view of  | 84 |  |
|    | 1.  |                        | ect matter claimed by the 135 Patent claim 1 would been obvious to the person of ordinary skill   | 86 |  |
|    |     | (a)                    | "A method of treating a subject suffering from hyperlipidemia or hypercholesterolemia, the method comprising"   | 87 |  |
|    |     | (b)                    | "Administering to the subject an effective amount of an MTP inhibitor"  | 88 |  |
|    |     | (c)                    | "Wherein said administration comprises at least<br>three step-wise, increasing dose levels of the MTP<br>inhibitor"   | 89 |  |
|    |     | (d)                    | "Wherein a first dose level is from about 2 to about 13 mg/day, a second dose level is from about 5 to about 30 mg/day, and a third dose level is from about 10 to about 50 mg/day" | 90 |  |
|    |     | (e)                    | "Wherein the MTP inhibitor is represented by:   |    |  |
|    |     |                        | CF <sub>3</sub>   |    |  |
|    |     |                        | or a pharmaceutically acceptable salt thereof or the piperidine N-oxide   |    |  |
|    |     |                        | thereof"  | 91 |  |
|    |     | (f)                    | "Wherein each dose level is administered to the subject for about 1 to about 5 weeks."  | 91 |  |
|    |     | (g)                    | The ordinarily skilled artisan would be motivated   |    |  |

# Declaration of Randall M. Zusman, M.D. Petition for *Inter Partes* Review of U.S. Patent No. 8,618,135

|     |                          |         |                          | to combine Stein 2004 with Chang  | 91  |  |
|-----|--------------------------|---------|--------------------------|---|-----|--|
|     |                          |         | (h)                      | The ordinarily skilled artisan would have a reasonable expectation of success | 97  |  |
|     |                          | 2.      | 135                      | Patent Claim 2  | 99  |  |
|     |                          | 3.      | 135                      | Patent Claim 3  | 101 |  |
|     |                          | 4.      | 135                      | Patent Claim 4  | 103 |  |
|     |                          | 5.      | 135                      | Patent Claim 5  | 104 |  |
|     |                          | 6.      | 135                      | Patent Claim 6  | 105 |  |
|     |                          | 7.      | 135                      | Patent Claim 7  | 106 |  |
|     |                          | 8.      | 135                      | Patent Claim 8  | 107 |  |
|     |                          | 9.      | 135                      | Patent Claim 9  | 109 |  |
|     |                          | 10.     | 135                      | Patent Claim 10   | 112 |  |
|     | E. Clair                 | m Cha   | rts                      | 114   |     |  |
|     |                          | 1.      | The                      | Pink Sheet in view of Chang   | 114 |  |
|     |                          | 2.      | Steir                    | n 2004 in view of Chang   | 124 |  |
| IX. | SECONDARY CONSIDERATIONS |         |                          |   |     |  |
|     | A.                       | No U    | Unexpected Results       |   |     |  |
|     | B.                       | No I    | Failure                  | of Others   | 138 |  |
|     | C.                       | No S    | No Skepticism in the Art |   |     |  |
| X   | COI                      | VCI IIS | SION                     |   | 140 |  |



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

# **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

